BioNTech’s Insider Sale Doesn’t Deter Wall Street as Oncology Pipeline Takes Center Stage

The German biotech has clawed back more than 22 percent from its March nadir of €72.50, closing Friday at €88.75. That puts the stock comfortably above its 50-day moving average of €84.31, a technical milestone that had looked distant just weeks ago. Yet the week’s 16 percent rally — the strongest in months — was punctuated by a 2.5 percent dip on Friday, a textbook profit-taking pattern that also coincided with news of a major insider sale.

Chief Operating Officer Sierk Poetting unloaded a block of shares worth roughly $5.5 million on Wednesday, reducing his direct stake by about 11 percent. The transaction was executed through a pre-arranged trading plan, but its proximity to next week’s earnings report gave some investors pause. The sale came just as the stock was riding a wave of optimism around the company’s pivot from COVID-19 vaccine maker to oncology powerhouse.

A Pipeline That Speaks Louder Than Insider Moves

Wall Street analysts have largely shrugged off the insider selling, instead training their focus on the clinical momentum building in BioNTech’s cancer portfolio. The company released positive Phase 2 data in April for its antibody-drug conjugate Trastuzumab Pamirtecan, targeting pretreated advanced endometrial carcinoma. The candidate already carries both Fast Track and Breakthrough Therapy designations from the FDA, with a regulatory submission penciled in for 2026.

Bank of America recently lifted its price target to $130, citing the strength of that ADC data. BMO Capital Markets set a similar target of $128. The average of 13 analyst ratings lands at “Strong Buy,” with a consensus target of $133.46 — implying roughly 23 percent upside from current levels.

The oncology pivot isn’t the only string in BioNTech’s bow. The company is also advancing vaccine candidates against malaria and Mpox, broadening its pipeline beyond the infectious disease work that made it a household name during the pandemic.

Should investors sell immediately? Or is it worth buying BioNTech?

The Numbers That Matter on May 5

BioNTech will report first-quarter 2026 results on Tuesday, May 5, with a conference call and webcast scheduled for 2:00 p.m. MEZ. The consensus forecast calls for a loss of $2.52 per share, a decline of nearly 39 percent year-over-year. Revenue is expected at roughly $215 million, up about 12 percent — though that modest top-line growth masks a deeper challenge.

Earnings per share estimates have been slashed by more than 27 percent over the past 30 days, reflecting the accelerating decline of COVID-19 vaccine sales. Management has been blunt about the transition: full-year 2026 revenue is forecast internally at $2.2 billion to $2.5 billion, below market expectations. The company’s future growth depends entirely on its oncology pipeline, with first commercial launches from that portfolio not expected until 2027 or 2028.

To fund the ambitious clinical program — which includes six new Phase 3 studies planned for this year alone — BioNTech has proposed an authorization to issue up to roughly 130 million new shares. That capital raise, combined with the insider sale, has injected a note of caution into an otherwise buoyant narrative.

Chart Support and the Road Ahead

Despite Friday’s pullback, the technical picture has improved markedly. The stock has reclaimed its 200-day moving average, a level that trend-following investors watch closely. The 52-week high of €105.90 remains a distant target, but the recovery from the March low of €72.50 has been swift and decisive.

The real test comes Tuesday. Investors will be listening less for COVID-19 revenue updates and more for concrete timelines on the oncology pipeline’s regulatory path. With $5.5 million in insider selling now public and a shareholder vote on the capital increase looming, BioNTech’s management has a narrow window to convince the market that the cancer bet will pay off before the COVID cash cushion fully deflates.